Comparative Pharmacology
Head-to-head clinical analysis: LEVORA 0 15 30 21 versus VIORELE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVORA 0 15 30 21 versus VIORELE.
LEVORA 0.15/30-21 vs VIORELE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
VIORELE is a monoclonal antibody that binds to and inhibits the activity of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
50 mg orally once daily
None Documented
None Documented
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Terminal elimination half-life of 12–15 hours (mean 13.5 h) in healthy adults; may be prolonged in renal impairment (up to 30 h).
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Primarily renal (unchanged drug and metabolites, ~60%) and fecal (~30%), with minor biliary contribution (~10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive